目的:探讨房颤患者血清CCN5水平是否可以预测左房低电压面积(LVZ)的大小。方法:选取2023年6月到2024年1月于烟台毓璜顶医院就诊的窦性心律患者(对照组) 79例以及首次接受心脏射频消融术的房颤患者(房颤组)114例。收集一般资料、生化、...目的:探讨房颤患者血清CCN5水平是否可以预测左房低电压面积(LVZ)的大小。方法:选取2023年6月到2024年1月于烟台毓璜顶医院就诊的窦性心律患者(对照组) 79例以及首次接受心脏射频消融术的房颤患者(房颤组)114例。收集一般资料、生化、心电图、心脏超声等临床资料。按术中行基质电压标测所得的LVZ是否大于6%将患者分为A组(LVZ Objective: To explore whether the serum CCN5 levels associated with atrial fibrosis can predict LVZ in patients with atrial fibrillation. Methods: In this study, 79 patients with sinus rhythm (control group) and 114 patients with atrial fibrillation (atrial fibrillation group) who received radiofrequency cardiac ablation for the first time in Yantai Yuhuangding Hospital between June 2023 and January 2024 were enrolled. General data, biochemistry, electrocardiogram, cardiac ultrasound and other clinical data were collected. Left atrial stroma voltage mapping was performed in patients with atrial fibrillation and LVZ area ratio was calculated. Patients were divided into group A (LVZ < 6%) and group B (LVZ ≥ 6%) according to whether LVZ was greater than 6%. The expression level of CCN5 in peripheral blood was measured by enzyme-linked immunosorbent assay. T test was used to compare the CCN5 expression level between the control group and the atrial fibrillation group. Pearson or Spearman correlation analysis was used to explore the correlation between CCN5 and clinical data. Binary Logistic regression analysis was used to determine the risk factors affecting the LVZ, and receiver operating characteristic (ROC) analysis was down to determine the cut-off value of CCN5 to predict LVZ. Results: The level of CCN5 in patients with atrial fibrillation was lower than in control group (32.43 ± 6.15 vs. 25.46 ± 4.97, P < 0.001). For atrial fibrillation patients with LVZ < 6%, blood CCN5 expression levels were lower in patients with LVZ ≥ 6% (30.10 ± 6.75 vs. 24.75 ± 3.49, P < 0.001). In patients with atrial fibrillation, CCN5 was negatively correlated with BNP level, left atrial diameter and left atrial low-voltage area ratio (P < 0.05). Logistic regression analysis suggested that blood CCN5 level was an independent risk factor for LVZ. ROC curve showed that in patients with atrial fibrillation, the optimal blood concentration of CCN5 to predict LVZ ≥ 6% was 27.22 ng/ml, sensitivity was 0.707, specificity was 0.773, and area under the curve was 0.785 [P < 0.001, CI: (0.696, 0.873)]. Conclusion: Serum CCN5 can independently predict the proportion of left atrial low-voltage area in patients with atrial fibrillation.展开更多
通过1986～1988年对浙江、江苏两省主要产梅区的梅树流胶病病害标本的采集、病原菌的分离培养和接种试验,证明了引起梅树流胶病的病原真菌有两种:葡萄座腔菌[Botryosphaeria dothidea(Moung. ex Fr.)Ces. & de Not(Syn B. ribis Gro...通过1986～1988年对浙江、江苏两省主要产梅区的梅树流胶病病害标本的采集、病原菌的分离培养和接种试验,证明了引起梅树流胶病的病原真菌有两种:葡萄座腔菌[Botryosphaeria dothidea(Moung. ex Fr.)Ces. & de Not(Syn B. ribis Gross & Dugg.)]和可可球二孢菌(Botryodiplodia theobromae Pat. (Syn.Lasiodiplodia theobromae(Pat.)Griff & Maub 1.)]分别引起枝腐型流胶和干腐型流胶。两种病菌的菌落只有在有光照射下才能形成分生孢子。B.dothidea的分生孢子萌发后通过皮孔、伤口和叶痕侵入枝干、枝梢,该病原除危害梅树外,还能危害桃、李、杏、樱桃等核果类果树。Bd.theobromae在梅树上的寄生危害在国内外尚属首次报道。展开更多
文摘目的:探讨房颤患者血清CCN5水平是否可以预测左房低电压面积(LVZ)的大小。方法:选取2023年6月到2024年1月于烟台毓璜顶医院就诊的窦性心律患者(对照组) 79例以及首次接受心脏射频消融术的房颤患者(房颤组)114例。收集一般资料、生化、心电图、心脏超声等临床资料。按术中行基质电压标测所得的LVZ是否大于6%将患者分为A组(LVZ Objective: To explore whether the serum CCN5 levels associated with atrial fibrosis can predict LVZ in patients with atrial fibrillation. Methods: In this study, 79 patients with sinus rhythm (control group) and 114 patients with atrial fibrillation (atrial fibrillation group) who received radiofrequency cardiac ablation for the first time in Yantai Yuhuangding Hospital between June 2023 and January 2024 were enrolled. General data, biochemistry, electrocardiogram, cardiac ultrasound and other clinical data were collected. Left atrial stroma voltage mapping was performed in patients with atrial fibrillation and LVZ area ratio was calculated. Patients were divided into group A (LVZ < 6%) and group B (LVZ ≥ 6%) according to whether LVZ was greater than 6%. The expression level of CCN5 in peripheral blood was measured by enzyme-linked immunosorbent assay. T test was used to compare the CCN5 expression level between the control group and the atrial fibrillation group. Pearson or Spearman correlation analysis was used to explore the correlation between CCN5 and clinical data. Binary Logistic regression analysis was used to determine the risk factors affecting the LVZ, and receiver operating characteristic (ROC) analysis was down to determine the cut-off value of CCN5 to predict LVZ. Results: The level of CCN5 in patients with atrial fibrillation was lower than in control group (32.43 ± 6.15 vs. 25.46 ± 4.97, P < 0.001). For atrial fibrillation patients with LVZ < 6%, blood CCN5 expression levels were lower in patients with LVZ ≥ 6% (30.10 ± 6.75 vs. 24.75 ± 3.49, P < 0.001). In patients with atrial fibrillation, CCN5 was negatively correlated with BNP level, left atrial diameter and left atrial low-voltage area ratio (P < 0.05). Logistic regression analysis suggested that blood CCN5 level was an independent risk factor for LVZ. ROC curve showed that in patients with atrial fibrillation, the optimal blood concentration of CCN5 to predict LVZ ≥ 6% was 27.22 ng/ml, sensitivity was 0.707, specificity was 0.773, and area under the curve was 0.785 [P < 0.001, CI: (0.696, 0.873)]. Conclusion: Serum CCN5 can independently predict the proportion of left atrial low-voltage area in patients with atrial fibrillation.
